VXLLF (Vaxil Bio) Other Stockholders Equity: $0.05 Mil (As of Mar. 2026)


VXLLF Vaxil Bio Ltd VXLLF
38 GF Score
Price $0.04
! 2 Warning Signs
View Full Analysis

What is Vaxil Bio Other Stockholders Equity?

Vaxil Bio VXLLF 38 Other Stockholders Equity is $0.05 Mil as of Mar. 2026. GuruFocus rates VXLLF with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

Vaxil Bio's Other Stockholders Equity for the quarter that ended in Mar. 2026 was $0.05 Mil.

Vaxil Bio's quarterly Other Stockholders Equity increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.05 Mil) and increased from Dec. 2025 ($0.05 Mil) to Mar. 2026 ($0.05 Mil).

Vaxil Bio's annual Other Stockholders Equity increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) and increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.05 Mil).

Vaxil Bio Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Vaxil Bio's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxil Bio Other Stockholders Equity Chart

Vaxil Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.24 0.00 0.00 0.05

Vaxil Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.05 0.05
VXLLF
38GF Score
Vaxil Bio Ltd VXLLF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxil Bio Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $0.05 Mil mean?
Vaxil Bio (VXLLF) has a Other Stockholders Equity of $0.05 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Vaxil Bio and its competitors.
Is Vaxil Bio's Other Stockholders Equity too high?
Vaxil Bio's current Other Stockholders Equity is $0.05 Mil. Overall, Vaxil Bio has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Vaxil Bio's Other Stockholders Equity compare to VRTX and REGN?
Vaxil Bio's Other Stockholders Equity of $0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Vaxil Bio and its competitors. Vaxil Bio's current Other Stockholders Equity is $0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxil Bio stock overvalued right now?
Vaxil Bio (VXLLF) has a current Other Stockholders Equity of $0.05 Mil. The current Other Stockholders Equity is $0.05 Mil. Vaxil Bio's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Vaxil Bio (VXLLF), the current Other Stockholders Equity is $0.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxil Bio Business Description

Other Exchanges VXL:Canada
Address 559 Briar Hill Avenue, Toronto, ON, CAN, M5N 1N1
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
38GF Score

Get the complete analysis for VXLLF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04
Price